deepseek

SciTechDaily – Science, Space and Technology News 2025

Top Science and Technology Breakthroughs of 2025 The year 2025 is shaping up to be a landmark period for scientific and technological advancements. From artificial intelligence to space exploration, groundbreaking innovations are set to redefine industries and improve lives. In this article, we’ll explore the most exciting breakthroughs expected in 2025, offering a glimpse into

SciTechDaily – Science, Space and Technology News 2025 Read More »

Safe Driving Possible Despite Loss of Visual Field

Safe Driving Tips for People with Visual Field Loss Driving is a crucial aspect of independence for many individuals, but for those with visual field loss, it can present unique challenges. Conditions like glaucoma, retinitis pigmentosa, or hemianopia can reduce peripheral or central vision, making driving more difficult. However, with the right strategies, many people

Safe Driving Possible Despite Loss of Visual Field Read More »

TLR4 deficiency does not alter glaucomatous progression in a mouse model of chronic glaucoma

TLR4 Deficiency Does Not Affect Glaucoma Progression in Mice Glaucoma is a leading cause of irreversible blindness worldwide, characterized by progressive optic nerve damage and retinal ganglion cell (RGC) loss. While elevated intraocular pressure (IOP) is a major risk factor, the underlying molecular mechanisms remain incompletely understood. Recent studies have explored the role of innate

TLR4 deficiency does not alter glaucomatous progression in a mouse model of chronic glaucoma Read More »

MIGS Offers Multiple Methods of Addressing Glaucoma Early: Christine Funke, MD

Early Glaucoma Treatment: MIGS Options Explained by Christine Funke, MD Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Early detection and treatment are crucial to preserving vision and preventing further damage. One of the most promising advancements in glaucoma management is Minimally Invasive Glaucoma Surgery (MIGS). In this article, Dr.

MIGS Offers Multiple Methods of Addressing Glaucoma Early: Christine Funke, MD Read More »

Study: Using pilocarpine drops post goniotomy may reduce long-term glaucoma medication needs

Pilocarpine Drops After Goniotomy May Lower Glaucoma Medication Use Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. While surgical interventions like goniotomy can help lower intraocular pressure (IOP), patients often still require multiple medications post-surgery. However, recent research suggests that using pilocarpine drops after goniotomy may significantly reduce the need

Study: Using pilocarpine drops post goniotomy may reduce long-term glaucoma medication needs Read More »

“We need policymakers to realise how important glaucoma is”

Why Policymakers Must Prioritize Glaucoma Awareness Now Glaucoma is often called the “silent thief of sight” because it progresses slowly and without noticeable symptoms until irreversible vision loss occurs. Despite being a leading cause of blindness worldwide, public awareness remains alarmingly low. Policymakers must act now to prioritize glaucoma awareness, early detection, and accessible treatment

“We need policymakers to realise how important glaucoma is” Read More »

Changes in corneal higher-order aberrations following PreserFlo MicroShunt implantation

How PreserFlo MicroShunt Affects Corneal Aberrations The PreserFlo MicroShunt is a minimally invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure (IOP) in patients with glaucoma. While its primary function is to improve aqueous outflow, recent studies have explored its impact on corneal aberrations—a critical factor in visual quality. This article delves into how

Changes in corneal higher-order aberrations following PreserFlo MicroShunt implantation Read More »

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial

Nicox Reports Whistler Phase 3b Glaucoma Trial Exploratory Results Nicox, a leading ophthalmic pharmaceutical company, has recently unveiled the exploratory results from its Whistler Phase 3b clinical trial for glaucoma treatment. The findings provide valuable insights into the efficacy and safety of their investigational drug, marking a significant milestone in the fight against this sight-threatening

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Read More »

Scroll to Top